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Cancer survival continues to improve, and thus cardiovascular consequences of chemotherapy are increasingly
important determinants of long-termmorbidity andmortality. Conventional strategies to protect the heart from
chemotherapy have important hemodynamic or myelosuppressive side effects. Remote ischemic conditioning
(RIC) using intermittent limb ischemia-reperfusion reduces myocardial injury in the setting of percutaneous
coronary intervention. Anthracycline cardiotoxicity and ischemia-reperfusion injury share commonbiochemical
pathways in cardiomyocytes. The potential for RIC as a novel treatment to reduce subclinical myocyte injury in
chemotherapy has never been explored andwill be investigated in the Effect of Remote Ischaemic Conditioning
in Oncology (ERIC-ONC) trial (clinicaltrials.gov NCT 02471885). The ERIC-ONC trial is a single-center, blinded,
randomized, sham-controlled study. We aim to recruit 128 adult oncology patients undergoing anthracycline-
based chemotherapy treatment, randomized in a 1:1 ratio into 2 groups: (1) sham procedure or (2) RIC,
comprising 4, 5-minute cycles of upper arm blood pressure cuff inﬂations and deﬂations, immediately before
each cycle of chemotherapy. The primary outcome measure, deﬁning cardiac injury, will be high-sensitivity
troponin-T over 6 cycles of chemotherapy and 12 months follow-up. Secondary outcome measures will
include clinical, electrical, structural, and biochemical endpoints comprising major adverse cardiovascular
clinical events, incidence of cardiac arrhythmia over 14 days at cycle 5/6, echocardiographic ventricular
function, N-terminal pro-brain natriuretic peptide levels at 3 months follow-up, and changes in mitochondrial
DNA, micro-RNA, and proteomics after chemotherapy. The ERIC-ONC trial will determine the efﬁcacy of
RIC as a novel, noninvasive, nonpharmacological, low-cost cardioprotectant in cancer patients undergoing
anthracycline-based chemotherapy.
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Introduction
Cancer affects more than 1 in 3 people in their lifetime and,
together with cardiovascular diseases, remains the leading
causes of morbidity and mortality in developed nations.
Cancer outcomes continue to improve such that long-term
10-year survival for all cancers now stands at 50%, and
80% or better for breast, prostate, Hodgkin’s lymphoma,
and melanoma.1 Cancer survivors will make up more than
5% of the US population by 2022,2 and nearly 25% of the
UK population aged 65 years and older by 2040.3 These
welcome improvements in primary cancer outcomes give
72 Clin. Cardiol. 39, 2, 72–82 (2016)
Published online in Wiley Online Library (wileyonlinelibrary.com)
DOI:10.1002/clc.22507
Received: August 21, 2015
Accepted with revision: November 15, 2015
© 2016 The Authors. Clinical Cardiology published by Wiley Periodicals, Inc.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited.
rise to a substantial survivor population at risk of long-
term cardiovascular consequences, either due to the cancer
treatment itself or due to traditional cardiovascular risks.
Cardiovascular mortality in cancer patients is increased due
to adverse coronary outcomes,4 and one-third of long-term
cancer survivors will die from cardiovascular causes.5
Even in the era of targeted cancer treatments, anthracy-
clines, either alone or in combination, remain the mainstay
for many types of cancer treatments including breast, lym-
phoma, sarcoma, and leukemia, but are almost invariably
limited by systemic and cardiac side effects. Thus, can-
cer cardioprotection is an important aspect of long-term
patient care.
Cardiotoxicity of Anthracyclines
Anthracyclines exert their cytotoxic effect via topoiso-
merase II inhibition and intercalation of DNA.6 However,
this effective—but nonselective—antitumor mechanism
has cardiotoxic consequences. Anthracycline cardiotoxicity
is classically attributed to lipid peroxidation and iron-
complex reactive oxidation species (ROS),7–10 to which
the myocyte is particularly vulnerable owing to a lack of
catalase, glutathione peroxidase, and limited regenerative
capacity.11–13 Cardiomyocytes are vulnerable to anthracy-
cline injury because they express topoisomerase II-β,10,14 but
additional myocyte damage is caused through calcium dys-
regulation and mitochondrial permeability transition pore
(MPTP) disruption.15–17
Anthracycline cardiotoxicity, defined initially as clinical
heart failure, was reported soon after the anthracyclines’
widespread introduction in the 1960s.18 This led to the
current practice of limiting the cumulative doxorubicin
dose to a lower cutoff of 400 mg/m2. Longitudinal studies
documented high mortality from anthracycline-induced
congestive heart failure—60% at 2 years18–20 —with image-
based subclinical cardiac dysfunction occurring in at least
9%21 to 18%.22
Cardioprotection
Cardioprotection to limit myocardial damage from anthra-
cycline chemotherapy has to date focused on 2 approaches:
modified doxorubicin preparations and pharmacological
treatments. Revised infusion strategies using lower dose,23
continuous infusion,24 liposomal doxorubicin,25,26 iron
chelation,27–29 and anti–heart failure medications have all
demonstrated some success in mitigating myocardial injury.
Up to half of myocyte cell death during acute myocar-
dial infarction is caused by reperfusion itself. Murry et al
described ischemic conditioning as endogenous activation
of cardioprotective mechanisms to limit myocardial infarct
size through repeated cycles of ischemia-reperfusion.30
Anthracycline cardiotoxicity and reperfusion cause myocyte
injury via common signaling pathways and molecular tar-
gets (Figure 1). Liposomal peroxidation, reactive oxidation
species, calcium overload,31–33 and mitochondrial respi-
ration/gene expression17,34–37 are affected in both injury
processes. Thus, remote ischemic preconditioning, cardio-
protective in ischemic injury, may also confer cardioprotec-
tion from anthracycline chemotherapy.
The Effect of Remote Ischaemic Conditioning in Oncology
Patients Study
Hypothesis
Remote ischemic conditioning (RIC), via repeated cycles of
inflation and deflation of a peripheral arm blood pressure
cuff, reduces myocardial injury in anthracycline-treated
cancer patients.
Study Objectives
The Effect of Remote Ischaemic Conditioning in Oncology
Patients (ERIC-ONC) study will be a proof-of-concept study
to investigate the effect of RIC in oncology patients. The
study objective is to determine whether RIC reduces
cardiac biomarker evidence of subclinical myocardial
cardiotoxicity during anthracycline-based chemotherapy
treatment. Primary and secondary outcome measures are
detailed in the Study Endpoints section and summarized in
Table 1.
Methods
Study Design
The ERIC-ONC study will be a single-center, blinded,
randomized, sham-controlled trial. The ERIC-ONC study
has been reviewed and approved with a favorable opinion
from the United Kingdom National Research Ethics Service
(NRES) (London-Chelsea Committee NRES REC reference:
15/LO/1116). The ERIC-ONC study protocol is registered
on the public trials database clinicaltrials.gov NCT 02471885
(Figure 2).
Study Population
The ERIC-ONC study will be conducted at a single
tertiary cancer referral center in London, United Kingdom.
Patient inclusion criteria are summarized in Table 2.
Participants will be recruited from adult oncology patients
newly referred for anthracycline chemotherapy (Eastern
Cooperative Oncology Group performance status <3), 18 to
80 years of age, who can provide informed consent (based
on Cancer Research United Kingdom data38 documenting
one-third of all new cancers were diagnosed in patients 75
years old and older, with the 50- to 74-year-old age group
accounting for 43% of all cancer deaths).
Patients will be excluded if they have had a recent
myocardial infarction (acute coronary syndrome) in the
previous 4 weeks, or have a defined cardiac diagnosis
that may raise baseline cardiac biomarkers above the
reference 99th centile such as dilated cardiomyopathy,
hypertrophic cardiomyopathy,39 cardiac amyloidosis,39,40
or Anderson-Fabry disease41 diagnosed or treated at our
tertiary cardiac center. Patients will also be excluded if
they have significant peripheral vascular disease defined
as upper limb claudication by symptoms or imaging,
chronic kidney disease with estimated glomerular filtration
rate <30 mL/min/1.73 m2, or taking sulfonylureas. Patients
unable to tolerate peripheral arm blood pressure cuff
inflation due to bilateral lymph node dissection, peripherally
inserted central catheter, or significant thrombocytopenia
(platelet count <100,000/μL) will be excluded.
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Figure 1. Reperfusion injury and doxorubicin cardiotoxicity pathways. Pathological activation of RoS formation, calcium overload, and altered
mitochondrial respiration in reperfusion injury are also found in anthracycline cardiotoxicity. (Reproduced under license from Yellon and Hausenloy86 and
the Massachusetts Medical Society/New England Journal of Medicine.). Abbreviations: ICAM-1, intercellular cell adhesion molecule-1; NADPH, nicotinamide
adenine dinucleotide phosphate hydrogen; PTP, permeability transition pore.
Chemotherapy Regimens
Participants recruited to the study will undergo, as part
of their standard cancer treatment, typically 6 cycles
of anthracycline-based chemotherapy occurring at 1 to
3 weekly intervals in the University College London
Hospital–Macmillan Cancer Centre. The participant’s usual
cancer chemotherapy care will only be altered along
standard clinical guidelines by their usual oncology team.
Intervention
The RIC intervention will be delivered as 4 cycles of
upper arm blood pressure cuff inflation to 200 mm Hg
(or 20 mm greater than systolic blood pressure) for 5
minutes to induce transient noninjurious limb ischemia,
followed by cuff deflation for 5 minutes. Participants
randomized to the sham control arm will receive 4 cycles
of upper arm blood pressure cuff inflation to 10 mm Hg
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Table 1. Study Outcome Measures
Outcome Endpoint Time Frame
Primary outcome High-sensitivity troponin-T Baseline, 6–24 hours after the end of each chemotherapy
infusion, 1, 3, 6, 12 months follow-up
Secondary outcomes Major adverse clinical cardiovascular event 1, 3, 6, 12 months follow-up
Myocardial infarction
Clinical heart failure requiring admission
Life-threatening arrhythmia (ventricular
tachycardia, ventricular ﬁbrillation)
Atrioventricular block requiring pacemaker
Cardiac or cancer death
Echocardiographic longitudinal function Baseline, 3, 12 months follow-up
Global longitudinal strain (%)
Incidence of cardiac arrhythmia Zio XT ambulatory ECG patch worn at start of chemotherapy cycle
5 of 6 (penultimate cycle) for 2 weeks continuous monitoring
Atrial ﬁbrillation/ﬂutter
Supraventricular tachycardia (AVNRT)
Ventricular tachycardia
Atrioventricular block
NT pro-BNP level Baseline, 3 months follow-up
MicroRNAa Baseline, 3 months
Mitochondrial DNAa
Urine proteomics and protein expression markersa
Abbreviations: AVNRT, atrioventricular nodal reentrant tachycardia; ECG, electrocardiogram; NT pro-BNP, N-terminal pro-brain natriuretic peptide.
aMetabolic markers for microRNA, mitochondrial DNA, and urine proteomics will be collected in 20 participants (control, n= 10; remote ischemic
conditioning, n= 10).
for 5 minutes to simulate treatment, followed by cuff
deflation for 5 minutes. Both treatments will last 40
minutes and will be applied before the start of planned
chemotherapy. If patients are unable to tolerate all 4 cycles
of cuff inflation, they will still be included in the study,
as there is evidence that a single cycle of RIC confers
cardioprotection.42
Randomization and Blinding
On the day of the first chemotherapy infusion, patients will
be randomly allocated in a 1:1 ratio to either the RIC or sham
group, using the following minimization factors: diabetes,
hypertension, and coronary artery disease to ensure that
groups are evenly matched in terms of cardiotoxicity
risk factors.22,43 Randomization will be performed using
MinimPy 0.3 software (http://minimpy.sourceforge.net) on
a laptop by an unblinded nurse specialist who will not be
involved in data analysis.
Study Endpoints
The primary outcome measure for the ERIC-ONC study
will be high-sensitivity troponin-T (hsTnT) measured at
baseline/prechemotherapy cycle, and at 6 to 24 hours
after chemotherapy cycles, then at 1, 3, 6, and 12 months
follow-up. Study outcome measures are summarized in
Table 1.
Secondary outcome measures will include a composite
clinical endpoint for major adverse cardiovascular clinical
events (MACCE) at 1, 3, 6, and 12 months follow-up,
defined as myocardial infarction, clinical heart failure
requiring admission, life-threatening cardiac arrhythmia,
atrioventricular block requiring pacemaker, or cardiac or
cancer death. Participants will be screened at regular
study visits for any MACCE leading to admission at
their local hospital or the tertiary center, adjudicated by
a cardiologist. These data will be entered onto an individual
case report form (CRF) and archived electronically onto
the Research Electronic Data Capture (REDCap) system.44
We intend to perform echocardiograms on a uniform GE
E9 ultrasound system (GE Healthcare, Waukesha, WI) to
measure ventricular chamber dimensions, ejection fraction,
and longitudinal strain at baseline, 3 months, and 12 months
using the TomTec Arena (TomTec Imaging Systems,
Unterschleissheim, Germany) speckle tracking package at
our core lab. Cardiac arrhythmia, at chemotherapy cycle
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Figure 2. Study ﬂowchart diagram. Abbreviations: BP, blood pressure; DCM, dilated cardiomyopathy; ECG, electrocardiogram; eGFR, estimated glomerular
ﬁltration rate; FBC, full blood count; HCM, hypertrophic cardiomyopathy; hsTnT, high-sensitivity troponin-T; LN, lymph node; NT pro-BNP, N-terminal
pro-brain natriuretic peptide; RIC, remote ischemic conditioning; U+ E, urea and electrolytes.
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Table 2. Study Participant Inclusion and Exclusion Criteria
Inclusion Criteria Exclusion Criteria
Adult cancer patients ages 18–80 years Recent myocardial infarction in previous 4 weeksa
Anthracycline regimen chemotherapy Previous diagnosis of dilated, hypertrophic, cardiac amyloidosis, or Anderson-Fabry disease
Able to tolerate upper arm blood pressure inﬂation Peripheral vascular disease with claudication on symptomatic or imaging criteria
Chronic kidney disease (estimated glomerular ﬁltration rate<30mL/min)
Taking sulphonylureas
Lymph node dissection/peripherally inserted central line precluding contralateral arm blood
pressure cuff inﬂation
aAcute myocardial infarction/acute coronary syndrome deﬁned according to the European Society of Cardiology, the American College of Cardiology, the
American Heart Association, and the World Heart Federation guidelines as detection of a rise of cardiac biomarker (eg, cardiac troponin I/T) with at least 1
value above the 99th centile upper reference limit with at least 1 of the following: symptoms of ischemia, new or presumed new signiﬁcant ST-T changes
or new left bundle branch block, pathological Q-waves on electrocardiogram, imaging evidence of loss of viable myocardium or new regional wall motion
abnormality, and intracoronary thrombus on angiography.51
5/6, will be documented over 14 days (Zio XT ECG patch;
CardioLogic, North Yorkshire, United Kingdom), defined
as atrial fibrillation/flutter, supraventricular tachycardia,
ventricular tachycardia, and atrioventricular block. The
oncology team will be notified if clinically significant
arrhythmia is documented. N-terminal pro-brain natriuretic
peptide levels, as a biomarker of raised left atrial pressure
and remodeling, will be recorded at baseline and 3 months
follow-up. We will compare in 10 control and 10 RIC
participants, changes in mitochondrial DNA, microRNA,
and urine proteomics and protein expression markers at
baseline and at 3 months.
Sample Size Calculations
There are no previous studies utilizing RIC to prevent
cardiotoxicity in chemotherapy. Most of the existing
evidence base for detecting chemotherapy cardiotoxicity
has utilized troponin-I assays. Troponin-positive thresholds
vary between each troponin-I assay, successive generations,
and the lone troponin-T assay. These disparities complicate
power calculations and preclude using the evidence base of
troponin-I cardiotoxicity studies for direct comparison. The
wide variation in troponin levels and study sizes is illustrated
in Table 3.
Power calculations for this pilot study were based on serial
troponin measurements treated as continuous outcome
variables with a predicted difference. Previous RIC studies
in the literature documented a cardioprotective effect of
reduced troponin release, ranging from −18 to −62%.45–48
We therefore hypothesized a predicted treatment effect of
−35% with 80% power at the 5% significance level, and
we calculated a sample size of 128 participants (n = 64 in
each arm of the study). This calculation was based on
the only hsTnT cardiotoxicity study to date by Katsurada
et al49 in breast cancer chemotherapy patients with and
without echocardiographically defined cardiotoxicity (using
peak hsTnT values as parameters to characterize the
troponin curve, with control [group 1] hsTnT = 11 ng/L,
standard deviation 7.8 ng/L, and RIC intervention [group
2], anticipated −35% difference to 7.15 ng/L, on 1:1 ratio,
with an α= 0.05, power = 80%).
Statistical Analysis
The effect of RIC treatment on hsTnT levels at baseline, at
6 to 24 hours and prior to each chemotherapy cycles, and at
3, 6, and 12 months, will be recorded a continuous variable.
Serial data at time points will be compared using a repeated
measures mixed effects model. We will analyze missing
data by intention to treat analysis and multiple imputation
in consultation with a statistician, depending on whether
the data were missing at random or not, respectively.
Categorical data will be analyzed using Fisher exact test or
χ2 test if frequency>5. We will use Cox proportional hazards
regression to calculate hazard ratios, and the Kaplan-Meier
function to visualize the cumulative incidence for MACCE.
Comparisons will be deemed statistically significant with a
P < 0.05.
Data Management, Governance, and Funding
The ERIC-ONC trial is funded under the National Institute
of Health Research Biomedical Research Centre and
sponsored by University College London. Data will be
collected on a CRF and managed using REDCap electronic
data capture tools. REDCap44 is a secure, Web-based
application designed to support validated and audited
data capture for research studies. An independent data
monitoring committee will be convened to monitor the
progress and safety of the study.
Discussion
There is no universally accepted definition of cardiotoxicity.
Historically, cardiotoxicity has been characterized along
clinical grounds (eg, overt heart failure) and more recently
by noninvasive imaging based on ejection fraction (ie,
either as a symptomatic 5% fall or an asymptomatic 10%
fall in ejection fraction to less than normal values).50
Current consensus guidelines suggest that biomarker rise
may be more sensitive in detecting early asymptomatic
cardiotoxicity to guide imaging assessment.50
In addition to its central role in the universal definition
of ACS51 and prognosis,52 troponin predicts outcomes in
other forms of heart disease,53–58 as well as anthracycline-
induced cardiotoxicity.59–61 The evidence base shows that
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Table 3. Troponin Assay Levels and Study Characteristics in Chemotherapy Cardiotoxicity Studies
Study Patient Mix M:F, Age
Trop+/Sample
Size (% Positive) Baseline Trop+ Tn Values (ng/L)
Troponin
Cutoff (ng/L) Troponin Assay
Cardinale
200098
Advanced cancer
with high-dose
chemotherapy1
39:165, 45± 10 y 65/204 (32%) 0% 1000± 400,
delta ejection
fraction, −18%
500 Stratus II TnI
Cardinale
200264
Breast cancer with
high-dose
chemotherapy2
211 F, 46± 11 y 70/211 (33%) 0% 900± 500 500 Stratus II TnI
Cardinale
200460
Advanced cancer
with high-dose
chemotherapy
216:487 47± 12 y 208/703 (30%) 0 % E: 160± 240,
event 1%, 37%,
84%
(see below)
80 Stratus CS TnI
Sandri 200399 Advanced cancer
with high-dose
chemotherapy
42:137, 47± 11 y (32%) delta
ejection fraction
18%
1% Tn+ 630± 540
(80–1980), Tn
neg= 39± 19
80 Stratus II CS TnI
Auner 200359 Hematological
adults
32:46, 58 y 78 (15%), delta
ejection fraction
>10%
0% Med 40
(30–120)
30 Roche ElecIII TnT
Lipshultz
200428
All children, Dox v,
Dex+Dexraz, RCT
120:86, 7.4 y 55/158 (35%) 12/119 (10%) Tn+ 50%,Tn++
32%; Dex 21%,
10%
10+ 25++ Roche Elecsys TnT
Kilickap 200561 Advanced
hematological
cancer with
high-dose
chemotherapy
20:21, 44 y (34%) N= 1 (16 ng/L) 10, ?100, error in
article
Roche ElecIII TnT
Haney 2013100 Breast cancer 22 F 41% (9/22) N/A Peak 60 ng/L,
cycle 6: 50%
Tn+
Tn+>12 ng/L;
TnT+ 22, samples
91
Roche TnT
Katsurada
201449
Breast cancer,
anthracy-
cline+ herceptin
19 F only, age N/A N= 19 hsTnT
values
N/A 11± 7.8,
4± 1.4
14 Roche hs-TnT
Abbreviations: Dex, Dexraz: Dexrazoxane; Dox: Doxorubicin; E: Early; hsTnT: high-sensitivity Troponin T; Med: Median; RCT: Randomized Controlled Trial;
Tn: Troponin; TnT: Troponin T.
This table illustrates the wide variation in troponin-I and troponin-T assays, troponin values, and study sizes. Although not directly comparable, we have
converted the levels to nanogram/liter (ng/L) here for simplicity. Peak troponin values in high-dose chemotherapy studies reached 1980 ng/L. Peak values
in low-dose studies reached 11–120 ng/L. Study sizes ranged from 19–703 participants. Studies routinely classiﬁed 30%–40% of patients as ‘‘troponin
positive’’ across various generations of troponin assays with differing cutoff values. We formulated several different power calculations to estimate
sample size for the study. The calculations were broadly grouped into 2 different models depending on whether we treated the primary outcome measure
for troponin levels as a categorical variable (a proportion of patients had a predeﬁned troponin-positive rise) or as a continuous variable (a difference
in troponin rise). If we treated troponin rise as a categorical (dichotomous) variable, whereby we stratiﬁed patients into early and late troponin-positive
versus troponin-negative responses based on Cardinale et al,60 a similar study would require either 42 or 586 patients, depending on whether the
cardioprotective effect prevented all early and late troponin-positive events or only early troponin positive events, respectively. Alternatively, treating
troponin as a continuous variable and using Cardinale et al60 and troponin levels stated in Table 3, the study would require 166 or 630 patients. Using
data from Sandri et al 2003,99 a study would require between 28 and 190 participants, based on a troponin difference of−590 or−220 ng/L, respectively.
Thus, our sample size of n= 128 total study participants falls in the middle range of our calculations for effect size and feasibility.
30% to 40% of anthracycline patients demonstrate a troponin-
positive trend during treatment, but these historical data
fluctuate according to troponin assay. Peak troponin-I/T
values, though not directly comparable, range from 11 to
120 ng/L, and 160 to more than 1000 ng/L, in low-dose and
high-dose anthracycline regimens, respectively (Table 3).
Myocardial injury and subsequent troponin release rises
progressively with cumulative anthracycline dose.61 There
is a single manufacturer of the hsTnT assay (Elecsys;
F. Hoffmann-La Roche, Basel, Switzerland). The current
generation Roche hs-TnT assay for the ERIC-ONC study
can be directly compared across all centers utilizing the
sole hs-TnT assay, enabling generalization of results and
facilitating comparison in future studies. This quantitative
1-step troponin-T enzyme immunoassay is specified with
a 10% coefficient of variation upper limit of normal set at
<14 ng/L, limit of detection = 5 ng/L, measurement range
3 to 10 000 ng/L.
The most widely used imaging measurement of car-
diotoxicity is ejection fraction, either by echocardiogram or
multigated acquisition scan, but this measurement
has important limitations in terms of precision and
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repeatability.62 Furthermore, morphological studies have
shown no linear association between biopsy findings and
ejection fraction.63 More recent work has demonstrated
biomarker evidence of myocardial injury even after the
first cycle of anthracycline therapy60,64 before a fall in ejec-
tion fraction, implying there may be no safe threshold
below which detectable myocardial injury does not occur.
Participants will undergo clinical and research echocar-
diograms according to clinical and study protocols. Imag-
ing evidence of subclinical cardiotoxicity, defined as an
asymptomatic fall in left ventricular ejection fraction of
≥10%, will be discussed with oncology for initiation of
angiotensin-converting enzyme inhibitor and/or β-blocker
therapy.65
Cardiac arrhythmia is common (in excess of 12%) in
cancer patients and affects morbidity and mortality,66,67
but prospective studies have been relatively small and
monitored for short durations.68,69 We will monitor
prospectively in all 128 participants the incidence of cardiac
arrhythmia. Participants will wear an electrocardiogram
patch after penultimate cycle 5 of chemotherapy treatment
for 14 days to span the period when we expect RIC to confer
antiarrhythmic protection43,69,70 from the cumulative effect
of anthracyclines,60,61,70 consistent with a putative role for
mitochondrial dysfunction in arrhythmogenesis.71
Pharmacological treatments to reduce myocyte damage
during chemotherapy include antioxidants, iron chelation,
and standard heart failure medications. Antioxidant strate-
gies have proved disappointing72,73; therapies such as
L-carnitine, co-enzyme Q10, N-acetylcysteine, and phenethy-
lamines have proved disappointing in children and equiv-
ocal in adults,74 possibly because antioxidants exert their
effect after free radical formation. Renin-angiotensin-system
inhibition,75 statin therapy,76 and β-blockers77,78 have shown
promise in adult cardioprotection,79,80 but their universal
adoption is constrained by interactions with renal func-
tion, transaminitis/myositis, and hemodynamic side effects,
respectively. Dexrazoxane is 1 of only 2 iron chelators
(along with deferiprone)27 that demonstrated cardioprotec-
tive effects28,29 by limiting cardiac troponin rise in pediatric
and adult hematological patients. However, dexrazoxane
may cause myelosuppression, and its regulatory license26
is limited to cancer patients embarking on extended
courses of anthracycline chemotherapy, rather than ini-
tial chemotherapy treatment. Furthermore, the incidence
of secondary malignancy following dexrazoxane remains
highly controversial.81–83 Thus, to date, pharmacological
interventions have demonstrated variable success and their
wider use limited by licensing constraints or side effect
profiles.
The phenomenon of ischemic conditioning as a form of
cardioprotection against ischemia was described by Murry
et al in 1986 as activation of endogenous cardioprotec-
tive mechanisms to limit myocardial infarct size through
repeated cycles of nonlethal ischemia-reperfusion before
an index episode of prolonged ischemic injury.30 Ischemic
conditioning exerts its cardioprotective effects via ligands
such as adenosine, bradykinin, and opioid cell surface
receptors acting on downstream signaling cascades involv-
ing recruitment of what has been termed the reperfusion
injury salvage kinase pathway. This in turn is thought to
cause inhibition of MPTP opening and inhibition of reactive
oxidation species ROS.84 Yellon’s group demonstrated that
mechanical RIC with a blood pressure cuff85,86 could also
confer cardioprotection via a noninvasive, nonpharmacolog-
ical technique.45,46
As a nonpharmacological treatment in the setting
of elective coronary artery bypass graft surgery, RIC
reduced myocardial injury by decreasing troponin rise
by 18% to 43%.45,46,48 RIC also decreased troponin rise
after primary percutaneous coronary intervention (PCI)
by 50% to 63%,47,87,88 improved myocardial salvage by
26%,89 and reduced myocardial infarction size by 27%.90
RIC was associated with decreased frequency of atrial
fibrillation by more than 50% in coronary artery bypass
grafting (CABG)45 and abolished it in a small series of
aortic valve replacement patients.91 RIC decreased the
incidence and extent of acute kidney injury by 30% in the
setting of elective high-risk cardiac surgery.92 It improved
medium-term clinical outcomes by reducing (MACCE
after CABG at 1.5 years,48 and in primary PCI by more
than 40% at a median follow-up of 3.8 to 4.3 years.87,93
RIC appears to exert a neutral effect on outcomes in
CABG surgery (the ERICCA study [Effect of Remote
Ischaemic Preconditioning on Clinical Outcomes in CABG
Surgery]; clinicaltrials.gov identifier NCT01247545),94,95
potentially due to the use of intraoperative propofol.95
Long-term outcomes in PCI are being investigated (ERIC-
PPCI study [Effect of Remote Ischaemic Conditioning on
Clinical Outcomes in STEMI Patients Undergoing PPCI];
clinicaltrials.gov NCT02342522). Cuff inflation is well-
tolerated with few side effects. Martin-Gill et al96 reported
the tolerability of RIC with 83% of 99 air ambulance transport
patients tolerating 3 or 4 cycles of RIC over 25 to 35 minutes,
with 53% reporting no pain and only 5% reporting moderate 5
out of 10 discomfort. Similarly, Li et al97 reported no adverse
effects in 216 patients.
To date, there are few studies applying RIC to
organ protection in cancer treatment and no comparable
studies investigating RIC cardioprotection in the setting
of cancer chemotherapy. Li et al97 demonstrated the
effectiveness of RIC in attenuating acute lung injury
in cancer patients, reducing oxygenation requirements
and postoperative stay in lung resection surgery. Thus,
RIC confers cardioprotection, renal protection, and lung
protection against ischemic injury.
The ERIC-ONC trial will be the first study to investigate
the efficacy of remote ischemic conditioning as a novel
form of noninvasive, nonpharmacological cardioprotection
against anthracycline chemotherapy. We anticipate our
study will establish the effectiveness of RIC to precondition
and protect the heart against subclinical biochemical,
structural, electrical, and metabolic cardiac injury in the
cardio-oncology setting as a pilot for a future multicenter
trial.
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